Discovery of α-glucosidase inhibitors from Paenibacillus sp. JNUCC 31 via genome mining, fatty acid profiling, and in silico analysis.

ABSTRACT: The increasing prevalence of type 2 diabetes has driven an increasing demand for safe and effective α-glucosidase inhibitors (AGIs). Given prior findings of α-glucosidase inhibitory activity in Paenibacillus spp., this study aims to evaluate the biosynthetic capacity and inhibitory potential of Paenibacillus sp. JNUCC 31. Genomic annotation of the strain JNUCC 31 revealed multiple biosynthetic gene clusters associated with secondary metabolite biosynthesis. Fatty acid profiling initially identified anteiso-C15:0 (57.32%) as the dominant fatty acid via GC-MS. Subsequently, the ethyl acetate extract from fermented cultures, which exhibited the highest α-glucosidase inhibitory activity (52.4 ± 0.7%), was purified and five known compounds were isolated: adenosine, uridine, 4-hydroxybenzaldehyd

SUBMITTER: Xu Y 

PROVIDER: S-EPMC12578816 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature